Australia markets closed

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.5574+0.2274 (+5.25%)
At close: 04:00PM EDT
4.7700 +0.21 (+4.66%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.3300
Open4.3100
Bid4.6100 x 800
Ask5.8000 x 1100
Day's range4.2900 - 4.5574
52-week range2.9700 - 17.9900
Volume1,835
Avg. volume20,708
Market cap169.537M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Vaccitech to Present at the H.C. Wainwright Global Investment Conference

    OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virt

  • GlobeNewswire

    Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “We’ve already made solid progress acr

  • GlobeNewswire

    Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

    Revenue Sharing Arrangement with University of Oxford Could Deliver Further Payments to Vaccitech Arising from Milestones and RoyaltiesOXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that it has been notified of the commencement of royalty payments relating to commercial sales of Vaxzevria®. Vaccitech’s share of mil